国际医学（000516.SZ）7月29日在投资者互动平台表示，西安国际医学中心医院老年护理院目前开放床 位100张，主要设全失能照护楼层、阿尔兹海默失能失智照护专区、生活护理照护楼层、医疗需求和康 复需求床位，房间分单人间、双人间、3-4人间和多人间，以满足各类入住长者的需求。 老年护理院依 托三级综合医院的医疗优势，可为入住长者提供日常就医、急危重症多学科会诊疗方案、优先转诊绿色 通道、康复训练、音乐疗愈、中医特色调理等全方位的服务。医养结合的康养项目是公司未来发展的重 要板块之一。 三级诊疗的区域性智能监测系统和家庭医生智能检测体系需要通过整合信息技术（如大 数据、人工智能、物联网等）对区域内的医疗资源、疾病动态和患者健康数据进行分层级管理，以实现 高效、精准的医疗资源分配和疾病防控。目前医院正在布局建设中。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：你好最近在贵公司国际医学微信小程序中看到推出了 国际医学中心医院老年护理院项目，并推出3天2晚的体验活动，不知道该老年养老护理院设计床位有多 少？能提供哪些服务？该项目是否会成为贵公司新的增长方向？其次贵公司是否有设计三级诊疗的 ...

证券日报网讯国际医学7月29日在互动平台回答投资者提问时表示，股东质押业务风险可控，不存在强 制抛售和平仓风险。从过往兑付来看，股东履约情况良好，具备兑付能力。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯国际医学7月29日在互动平台回答投资者提问时表示，公司股东世纪新元履约情况良好， 未出现欠息逾期情况。股东将通过短期与长期两个维度，平衡现金流与运营需求。 ...

证券日报网讯国际医学7月29日在互动平台回答投资者提问时表示，公司医疗主业稳健发展，关于公司 未来业绩的情况，请留意公司相关定期报告。公司将不断加强精细化运营，调整业务结构，提升运营质 效。一方面实施差异化经营策略，扩大服务规模；另一方面优化内部管理流程，提高运营效率。结合公 司发展阶段，目前资产负债率处于合理水平。随着公司已建成的整体医疗床位使用量稳步提升，经营业 绩的逐步改善，公司将进一步优化资本结构，降低负债水平。 （文章来源：证券日报） ...

Group 1 - The high-pressure oxygen chamber concept increased by 1.55%, ranking second among concept sectors, with three stocks rising, including a 20% limit up for Tiebian Heavy Industry [1] - The leading gainers in the high-pressure oxygen chamber sector were International Medicine and Yinkang Life, which rose by 0.93% and 0.20% respectively [1] - The sector saw a net inflow of 0.50 billion yuan from main funds, with Tiebian Heavy Industry receiving the highest net inflow of 1.03 billion yuan [2][3] Group 2 - The main fund inflow ratios for Tiebian Heavy Industry, International Medicine, and Jinling Pharmaceutical were 29.36%, 10.10%, and 5.54% respectively [3] - The trading performance of stocks in the high-pressure oxygen chamber sector showed varied results, with Tiebian Heavy Industry leading in both price increase and fund inflow [3][4] - Stocks such as Weiao and Innovation Medical experienced significant declines, with net outflows of -3214.35 million yuan and -4427.60 million yuan respectively [4]

Core Insights - The DRG (Diagnosis-Related Group) payment reform in China is set to deepen in 2025, aiming to optimize resource allocation, control costs, and improve medical efficiency [1] - The DRG/DIP (Disease Value Payment) system will cover all eligible medical institutions by the end of this year, transitioning to a fixed payment model based on disease grouping rather than itemized billing [1] - The adjustment in payment policies may suppress average costs and hospitalization rates in the short term, but will encourage healthcare institutions to focus on refined management and cost control in the long term [2] Company Strategies - The company is focusing on high CMI (Case Mix Index) disease categories such as neurosurgery and oncology, while also undertaking complex medical projects to establish a leading advantage [3] - The company is implementing a differentiated strategy by expanding into high-value medical health markets, including specialized services in areas like aesthetic medicine, reproductive health, and proton therapy [3][4] - The company has developed a comprehensive health service platform that integrates medical services, rehabilitation, and elderly care, aiming to enhance operational efficiency and overall performance [5] Market Positioning - The company is actively pursuing multi-dimensional strategies to adapt to the changing healthcare landscape, emphasizing refined operations, cost control, and revenue structure adjustments [2] - The establishment of the proton therapy center, expected to be operational by the end of 2025, positions the company as a key player in advanced cancer treatment in the Northwest region [4] - The company is leveraging its medical capabilities to provide VIP services and comprehensive health management, enhancing its competitive edge in the market [4][5]

Group 1 - The high-pressure oxygen chamber concept increased by 2.63%, ranking 10th among concept sectors, with five stocks rising, including a 20% limit-up for Tiedao Heavy Industry [1] - Notable gainers in the high-pressure oxygen chamber sector include Innovation Medical and Samsung Medical, which rose by 3.29% and 0.96% respectively [1] - The sector experienced a net inflow of 170 million yuan from main funds, with Tiedao Heavy Industry receiving the highest net inflow of 120 million yuan [2] Group 2 - The top stocks by net inflow ratio in the high-pressure oxygen chamber sector are Tiedao Heavy Industry at 39.19%, International Medical at 4.88%, and Samsung Medical at 4.16% [3] - The trading volume and turnover rates for key stocks in the sector indicate significant investor interest, with Tiedao Heavy Industry showing a turnover rate of 0.97% [3] - Decliners in the sector included Dahu Co., which fell by 0.55%, and Aoyang Health, which decreased by 0.50% [4]

Group 1 - The high-pressure oxygen chamber concept increased by 3.78%, ranking 8th among concept sectors, with 8 stocks rising, including a 20% limit up for Tiebian Heavy Industry [1] - The leading stocks in the high-pressure oxygen chamber sector included Weiao Co., International Medicine, and Dahu Co., which rose by 3.80%, 3.24%, and 2.44% respectively [1] - The high-pressure oxygen chamber sector saw a net inflow of 152 million yuan from main funds, with 6 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow [2] Group 2 - The top net inflow stock was Tiebian Heavy Industry, with a net inflow of 60.89 million yuan, followed by International Medicine, Samsung Medical, and Aoyang Health with net inflows of 57.53 million yuan, 42.20 million yuan, and 22.89 million yuan respectively [2] - In terms of net inflow ratios, Aoyang Health, Tiebian Heavy Industry, and International Medicine had the highest ratios at 15.77%, 14.47%, and 11.68% respectively [3] - The trading performance of stocks in the high-pressure oxygen chamber sector showed significant activity, with Tiebian Heavy Industry achieving a daily increase of 19.90% and a turnover rate of 1.60% [3]

Group 1 - The core viewpoint is that Shengdian Medical aims to establish a production base in the Sichuan-Chongqing region to enhance the biopharmaceutical industry chain and promote international medical cooperation [1] - Shengdian Medical has introduced a new type of conductive biomaterial developed by a team from the Royal Society of Canada, which resembles a "band-aid" and combines biological and conductive materials for minimally invasive implantation [1] - The company is in discussions with various districts in Chongqing and Sichuan to implement the conductive biomaterial project, leveraging the region's strategic position and industrial strength to foster connections with countries involved in the Belt and Road Initiative [1] Group 2 - The company is also establishing a cooperation base for Traditional Chinese Medicine (TCM) and Thai medicine in Thailand, aiming to integrate both cultures for the benefit of the local population [2] - There is a growing demand for health consumption among Chinese citizens, presenting new opportunities for the medical and health industry, which aligns with the global expansion of TCM [2]

Core Viewpoint - International Medical is facing significant financial challenges, with continued losses and high shareholder pledge rates raising concerns about its operational sustainability and debt risks [1][2][10]. Financial Performance - The company is projected to report a net loss of between 160 million to 170 million yuan for the first half of 2025, only slightly improved from a loss of 174 million yuan in the same period last year, indicating persistent operational difficulties [1][2]. - Since 2018, the company's net profit has been negative for seven consecutive years, highlighting ongoing profitability issues [2]. - Revenue for the first quarter of 2025 was 999.7 million yuan, with a net loss of 106 million yuan, reflecting continued pressure on profitability [2]. Asset and Debt Management - As of the end of Q1 2025, the company's asset-liability ratio stood at 67.64%, with interest-bearing liabilities nearing 4.599 billion yuan [6]. - The company has 472 million yuan in cash, which is insufficient to cover 851 million yuan in short-term loans and 861 million yuan in current non-current liabilities [6]. - The company's fixed asset scale has expanded to 7.131 billion yuan, leading to high fixed costs that are not being offset by revenue [4]. Shareholder Pledge Risks - The controlling shareholder's pledge ratio has increased to 27.49%, with 81.45% of their shares pledged, representing 22.39% of the total share capital [1][9]. - Recent announcements indicate that over 886 million shares have had their repurchase deadlines extended, suggesting deep financial strain on the shareholder [8][10]. - The high pledge ratio and upcoming debt maturities create a risk transmission chain that could impact the company's governance and operational stability [10]. Market Position and Future Outlook - The company has struggled to convert its large asset base into profitability, with a significant drop in revenue growth from 70.34% in 2023 to 14.99% in Q1 2025 [4]. - The market has re-evaluated the company's value, with its stock price dropping from a peak of 21.66 yuan per share in 2021 to 5.24 yuan per share in July 2023, reflecting declining investor confidence [10].